Cerebral Cavernous Malformations in Children

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Children's CCMs hemorrhage at about 2–3% per year overall, but about 11% per year after a bleed, clustered in the first 3 years .
  • Highest-risk features: prior hemorrhage, brainstem location and an associated DVA .
  • Hereditary forms:
    • Genetics: autosomal dominant KRIT1, CCM2 or PDCD10; KRIT1 Q455X is a Hispanic founder variant .
    • PDCD10 is the most aggressive genotype .
    • Familial children bleed at about 5% per year .
  • The three indications:

1. symptomatic hemorrhage (especially recurrent, or pial-reaching brainstem lesions); 2. epilepsy (85.7% Engel I after resection; LITT is an option); 3. growth or mass effect, including radiation-induced lesions .

  • Incidental and asymptomatic deep lesions: observe.
  • Prior radiation: expect de novo CCMs .

Landmark papers

  • Natural history in children (Gross et al., J Neurosurg Pediatr 2016): a single-center untreated cohort of 167 children (222 CCMs). The overall annual hemorrhage rate was 3.3% .
  • Treat_CCM (Lanfranconi et al., Lancet Neurol 2023): propranolol in 83 adults with symptomatic familial CCM. Symptomatic hemorrhage or new deficit occurred at 1.7 vs 3.9 per 100 person-years (HR 0.43), a signal of efficacy in a phase 2 pilot, not proof .

Cerebral cavernous malformations (CCMs, cavernomas) are clusters of thin-walled, endothelial-lined caverns with no intervening brain, ringed by hemosiderin.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:cavernous_malformation:411b829534c9126d© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Mulberry cluster of thin-walled caverns with a hemosiderin rim and an associated developmental venous anomaly; T2 popcorn appearance and multiple SWI dots in familial disease; a pontine lesion reaching the pial surface and a cortical lesion resected with its hemosiderin rim(A) MULBERRY LESION WITH HEMOSIDERIN RIM AND DVAthin-walled, endothelium-linedcaverns; no brain between themhemosiderin rim (gliotic,rust-brown) in surrounding braindevelopmental venous anomaly(caput medusae)collector vein to the surface(B) MRI: T2 “POPCORN” AND SWI (FAMILIAL, MULTIPLE)T2: reticulated core,dark hemosiderin rimSWI: multiple black dots(familial CCM)(C) SURGICAL TARGETSpons: lesion reaching the pialsurface (safe entry zone)cortical lesion: resect with thehemosiderin rim (epileptogenic)schematic; not to scale
Cerebral cavernous malformation. (a) Mulberry-like cluster of thin-walled caverns with a hemosiderin rim and an associated developmental venous anomaly. (b) MRI appearance: T2 "popcorn" lesion with a dark hemosiderin rim, and multiple SWI black dots in familial disease. (c) A brainstem lesion reaching the pial surface, and a cortical lesion resected with its epileptogenic hemosiderin rim. Original schematic.

Natural history in children

Hereditary forms

Indications for treatment

Treat when one of the following is present.

Medical therapy and precautions

Related topics

References

  1. Gross BA, Du R, Orbach DB, et al. The natural history of cerebral cavernous malformations in children. J Neurosurg Pediatr 2016;17(2):123–128. doi:10.3171/2015.2.PEDS14541. PMID 26474098. verified
  2. Santos AN, Rauschenbach L, Saban D, et al. Natural course of cerebral cavernous malformations in children: a five-year follow-up study. Stroke 2022;53(3):817–824. doi:10.1161/STROKEAHA.121.035338. PMID 34706565. verified
  3. Benichi S, Balducci E, Benzakoun J, et al. Clinical and molecular landscape of paediatric cerebral and spinal cavernous malformations. Brain Commun 2025;7(6):fcaf408. doi:10.1093/braincomms/fcaf408. PMID 41216139. verified
  4. Flemming KD, Smith E, Marchuk D, Derry WB. Familial cerebral cavernous malformations. In: Adam MP, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–; updated 2023. PMID 20301470. verified
  5. Choquet H, Nelson J, Pawlikowska L, et al. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis 2014;37(1):57–63. doi:10.1159/000356839. PMID 24401931. verified
  6. Shenkar R, Shi C, Rebeiz T, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med 2015;17(3):188–196. doi:10.1038/gim.2014.97. PMID 25122144. verified
  7. Geraldo AF, Alves CAPF, Luis A, et al. Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study. Neuroradiology 2023;65(2):401–414. doi:10.1007/s00234-022-03056-y. PMID 36198887. verified
  8. Keusch DS, Choi JH, Lopes C, et al. Operative management of pediatric radiation-induced cavernous malformations: insights from a single-center cohort. Childs Nerv Syst 2026;42(1). doi:10.1007/s00381-026-07359-w. PMID 42362942. verified
  9. Akers A, Al-Shahi Salman R, Awad IA, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665–680. doi:10.1093/neuros/nyx091. PMID 28387823. verified
  10. Choi JH, Albanese J, Riordan CP, et al. Management strategies and long-term outcomes of pediatric brainstem cavernous malformations: conservative management vs surgery. Neurosurgery 2026 (online ahead of print). doi:10.1227/neu.0000000000004042. PMID 41996091. verified
  11. Bosisio L, Cognolato E, Nobile G, et al. Surgical treatment of cavernous malformation-related epilepsy in children: case series, systematic review, and meta-analysis. Neurosurg Rev 2024;47(1):251. doi:10.1007/s10143-024-02491-0. PMID 38819574. verified
  12. Willie JT, Malcolm JG, Stern MA, et al. Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations. Epilepsia 2019;60(2):220–232. doi:10.1111/epi.14634. PMID 30653657. verified
  13. Lanfranconi S, Scola E, Meessen JMTA, et al. Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol 2023;22(1):35–44. doi:10.1016/S1474-4422(22)00409-400409-4). PMID 36403580. verified

Verification (2026-11-17):

Caveats: